Br Med J. 1969 Feb 8;1(5640):335-42.
This report describes the design and results of a controlled trial of anticoagulant drugs in the treatment of patients admitted to hospital suffering from acute myocardial infarction. A total of 1,427 patients were allocated at random to therapy with high-dosage or low-dosage anticoagulants. The high-dosage regimen was 36 hours of heparin administration and phenindione in doses to maintain the thrombotest level between 10 and 20%. The mean phenindione dosage was 72 mg./day. The low-dosage regimen consisted of 1-mg. tablets of phenindione. Therapy was continued for 28 days.There was no significant reduction in the mortality in the high-dosage group. Among the 712 patients allocated to high dosage 115 (16.2%) died before the 29th day of the trial. Of the 715 patients allocated to low dosage 129 (18%) died. This difference between these mortality rates could have occurred by chance.There was a significant reduction in the frequency of clinically evident thromboembolic complications (systemic artery occlusion, leg vein thrombosis, and pulmonary embolism) among patients in the high-dosage group. This did not, however, materially affect the difference in mortality from all causes.
本报告描述了一项关于抗凝药物治疗急性心肌梗死住院患者的对照试验的设计与结果。共有1427名患者被随机分配接受高剂量或低剂量抗凝治疗。高剂量方案为给予36小时的肝素,并给予苯茚二酮以维持凝血酶试验水平在10%至20%之间。苯茚二酮的平均剂量为72毫克/天。低剂量方案由1毫克的苯茚二酮片剂组成。治疗持续28天。高剂量组的死亡率没有显著降低。在分配到高剂量组的712名患者中,有115名(16.2%)在试验的第29天之前死亡。在分配到低剂量组的715名患者中,有129名(18%)死亡。这些死亡率之间的差异可能是偶然发生的。高剂量组患者临床上明显的血栓栓塞并发症(系统性动脉闭塞、腿部静脉血栓形成和肺栓塞)的发生率显著降低。然而,这并未实质性影响全因死亡率的差异。